← back to search

Darlene Lu

Novartis (United States) · US
Area of research
Oncology · Immunology
Research interest
Research interests include CAR-T cell therapy research, Biosimilars and Bioanalytical Methods, HIV/AIDS drug development and treatment, and Biomedical Ethics and Regulation.
h-index
18
citations
1,024
works
53
NIH funding
primary concept
email

Recent publications

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
Journal for ImmunoTherapy of Cancer 2023cited by 36position: middledoi
Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.
Journal of Clinical Oncology 2021cited by 38position: middledoi
Perceived racism in relation to telomere length among African American women in the Black Women's Health Study
Annals of Epidemiology 2019cited by 54position: firstdoi
Heterogeneity and Spatial Distribution of Intravertebral Trabecular Bone Mineral Density in the Lumbar Spine Is Associated With Prevalent Vertebral Fracture
Journal of Bone and Mineral Research 2019cited by 28position: middledoi
Correspondence between bone mineral density and intervertebral disc degeneration across age and sex
Archives of Osteoporosis 2018cited by 42position: middledoi
Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study
Clinical Infectious Diseases 2013cited by 67position: middledoi
Three Distinct Phases of HIV-1 RNA Decay in Treatment-Naive Patients Receiving Raltegravir-Based Antiretroviral Therapy: ACTG A5248
The Journal of Infectious Diseases 2013cited by 61position: middledoi
Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study
JAIDS Journal of Acquired Immune Deficiency Syndromes 2013cited by 15position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Marc R. Pelletier · Medieval Academy of America2 papers (2021–2023)Louise Barys · Novartis (Switzerland)2 papers (2021–2023)Jarred Kaiser · Atlanta VA Medical Center2 papers (2018–2019) · 2 papers (2021–2023)Anna Spreafico · University Health Network2 papers (2021–2023)Thomas Yau · Hôpital Pontchaillou2 papers (2021–2023)Armando Santoro · Humanitas University2 papers (2021–2023)Maria-Elisabeth Goebeler · Comprehensive Cancer Center Mainfranken2 papers (2021–2023)Edward P. Acosta · University of Alabama at Birmingham Hospital2 papers (2013–2013)Susan L. Rosenkranz · Frontier Science & Technology Research Foundation2 papers (2013–2013)Paul M. Fein · Boston University2 papers (2018–2019)Viviana Cremasco · Translational Research in Oncology2 papers (2021–2023)Elise F. Morgan · Boston University2 papers (2018–2019)Markus Joerger · Palmetto Hematology Oncology2 papers (2021–2023)Ignacio Garrido‐Laguna · University of Utah2 papers (2021–2023)Mary Bouxsein · Massachusetts Institute of Technology2 papers (2018–2019)Chia‐Chi Lin · National Taiwan University Hospital2 papers (2021–2023)Todd M. Bauer · The University of Texas MD Anderson Cancer Center2 papers (2021–2023)Richard Greil · EB House Austria2 papers (2021–2023)Mohamed Jarraya · Harvard University2 papers (2018–2019)